[{"orgOrder":0,"company":"Mercy Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Cefazolin","moa":"Bacterial penicillin-binding protein","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Mercy Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mercy Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mercy Health \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Diclofenac Potassium","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Rundo International Pharmaceutical Research & Development","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Indomethacin","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Rundo International Pharmaceutical Research & Development","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Rundo International Pharmaceutical Research & Development"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Naproxen","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"Seoul National University Bundang Hospital","sponsor":"JW Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SOUTH KOREA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Seoul National University Bundang Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Bundang Hospital \/ JW Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Bundang Hospital \/ JW Pharmaceutical"},{"orgOrder":0,"company":"International Clinical Research Institute","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"International Clinical Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"International Clinical Research Institute \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"International Clinical Research Institute \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Universitaire Ziekenhuizen KU Leuven","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Rocuronium Bromide","moa":"Muscle-type nicotinic acetylcholine receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Universitaire Ziekenhuizen KU Leuven","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universitaire Ziekenhuizen KU Leuven \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Universitaire Ziekenhuizen KU Leuven \/ Merck & Co"},{"orgOrder":0,"company":"Sanford Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Sanford Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanford Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanford Health \/ Undisclosed"},{"orgOrder":0,"company":"Hvidovre University Hospital","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"DENMARK","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Parathyroid Hormone (1-84)","moa":"Parathyroid hormone-1 receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Hvidovre University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hvidovre University Hospital \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Hvidovre University Hospital \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"University of Manitoba","sponsor":"Health Sciences Centre Winnipeg","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CANADA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"University of Manitoba","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Manitoba \/ Health Sciences Centre Winnipeg","highestDevelopmentStatusID":"11","companyTruncated":"University of Manitoba \/ Health Sciences Centre Winnipeg"},{"orgOrder":0,"company":"UConn Health","sponsor":"Orthopedic Research and Education Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"UConn Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"UConn Health \/ Orthopedic Research and Education Foundation","highestDevelopmentStatusID":"11","companyTruncated":"UConn Health \/ Orthopedic Research and Education Foundation"},{"orgOrder":0,"company":"Campbell Clinic","sponsor":"Duke University | The University of Pittsburgh School of Medicine | Endeavor Health | University of Cincinnati | Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Campbell Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Campbell Clinic \/ Duke University | The University of Pittsburgh School of Medicine | Endeavor Health | University of Cincinnati | Washington University School of Medicine","highestDevelopmentStatusID":"11","companyTruncated":"Campbell Clinic \/ Duke University | The University of Pittsburgh School of Medicine | Endeavor Health | University of Cincinnati | Washington University School of Medicine"},{"orgOrder":0,"company":"Inspire Health Medical Group","sponsor":"Arbi Nazarian, MD","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Inspire Health Medical Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inspire Health Medical Group \/ Arbi Nazarian, MD","highestDevelopmentStatusID":"11","companyTruncated":"Inspire Health Medical Group \/ Arbi Nazarian, MD"},{"orgOrder":0,"company":"Kendall Healthcare Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Kendall Healthcare Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kendall Healthcare Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Kendall Healthcare Group \/ Undisclosed"},{"orgOrder":0,"company":"Prisma Health-Upstate","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Mepivacaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Prisma Health-Upstate","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prisma Health-Upstate \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Prisma Health-Upstate \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"NETHERLANDS","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ ZonMw","highestDevelopmentStatusID":"11","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ ZonMw"},{"orgOrder":0,"company":"Northern Light Mercy Hospital","sponsor":"MaineHealth","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Northern Light Mercy Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Northern Light Mercy Hospital \/ MaineHealth","highestDevelopmentStatusID":"11","companyTruncated":"Northern Light Mercy Hospital \/ MaineHealth"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Virtua Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"5CC Vivigen","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Virtua Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virtua Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Virtua Health \/ Undisclosed"},{"orgOrder":0,"company":"Seton Healthcare Family","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"BIO4","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Seton Healthcare Family","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seton Healthcare Family \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Seton Healthcare Family \/ Undisclosed"},{"orgOrder":0,"company":"Hospital Clinic of Barcelona","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SPAIN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"HMB","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Hospital Clinic of Barcelona","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Clinic of Barcelona \/ Abbott Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Hospital Clinic of Barcelona \/ Abbott Laboratories"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"IPACK Block","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Odense University Hospital","sponsor":"Independent Research Fund Denmark","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Macrogol 3350","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Odense University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Odense University Hospital \/ Independent Research Fund Denmark","highestDevelopmentStatusID":"11","companyTruncated":"Odense University Hospital \/ Independent Research Fund Denmark"},{"orgOrder":0,"company":"Seton Healthcare Family","sponsor":"Celling Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Solum Iv","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Seton Healthcare Family","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seton Healthcare Family \/ Celling Biosciences","highestDevelopmentStatusID":"11","companyTruncated":"Seton Healthcare Family \/ Celling Biosciences"},{"orgOrder":0,"company":"GCS Ramsay Sant\u00e9","sponsor":"Euraxi Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"GCS Ramsay Sant\u00e9","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GCS Ramsay Sant\u00e9 \/ Euraxi Pharma","highestDevelopmentStatusID":"11","companyTruncated":"GCS Ramsay Sant\u00e9 \/ Euraxi Pharma"},{"orgOrder":0,"company":"Henry Ford Health System","sponsor":"SMITH & NEPHEW INC","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Henry Ford Health System","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Henry Ford Health System \/ SMITH & NEPHEW INC","highestDevelopmentStatusID":"11","companyTruncated":"Henry Ford Health System \/ SMITH & NEPHEW INC"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Olayemi Osiyemi MD","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ceftaroline Fosamil","moa":"Bacterial penicillin-binding protein","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Olayemi Osiyemi MD","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Olayemi Osiyemi MD"},{"orgOrder":0,"company":"Roche Diagnostics GmbH","sponsor":"Lene Bergendal Solberg","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Zoledronic Acid","moa":"Farnesyl diphosphate synthase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Roche Diagnostics GmbH","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roche Diagnostics GmbH \/ Lene Bergendal Solberg","highestDevelopmentStatusID":"11","companyTruncated":"Roche Diagnostics GmbH \/ Lene Bergendal Solberg"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Valera Bussell","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Valera Bussell","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Valera Bussell"},{"orgOrder":0,"company":"Radius Health","sponsor":"Daniel Horwitz","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Abaloparatide","moa":"Parathyroid hormone receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Radius Health \/ Daniel Horwitz","highestDevelopmentStatusID":"11","companyTruncated":"Radius Health \/ Daniel Horwitz"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Shane Burch","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Teriparatide","moa":"Parathyroid hormone receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Shane Burch","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Shane Burch"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Jose Soberon","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacira BioSciences \/ Jose Soberon","highestDevelopmentStatusID":"11","companyTruncated":"Pacira BioSciences \/ Jose Soberon"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Campbell Clinic

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Campbell Clinic

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Lead Product(s) : Tranexamic Acid

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Study Phase : Phase IV

                          Sponsor : Duke University | The University of Pittsburgh School of Medicine | Endeavor Health | University of Cincinnati | Washington University School of Medicine

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Tranexamic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Anterior Cruciate Ligament Injuries.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 11, 2025

                          Lead Product(s) : Tranexamic Acid

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase IV

                          Sponsor : Duke University | The University of Pittsburgh School of Medicine | Endeavor Health | University of Cincinnati | Washington University School of Medicine

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Inspire Health Medical Group

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Inspire Health Medical Group

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Tranexamic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Long Bone Fractures.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 11, 2025

                          Lead Product(s) : Tranexamic Acid

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase IV

                          Sponsor : Arbi Nazarian, MD

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          University of Manitoba

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          University of Manitoba

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Vancomycin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Fractures, Open.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          July 17, 2024

                          Lead Product(s) : Vancomycin Hydrochloride

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase IV

                          Sponsor : Health Sciences Centre Winnipeg

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Odense University Hospital

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Odense University Hospital

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Macrogol 3350 is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hip Fractures.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 12, 2024

                          Lead Product(s) : Macrogol 3350

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase IV

                          Sponsor : Independent Research Fund Denmark

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Prisma Health-Upstate

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Prisma Health-Upstate

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Mepivacaine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Arthroplasty, Replacement, Knee.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 04, 2024

                          Lead Product(s) : Mepivacaine Hydrochloride

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Northern Light Mercy Hospital

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Northern Light Mercy Hospital

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Bupivacaine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Arthroplasty, Replacement, Knee.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 02, 2022

                          Lead Product(s) : Bupivacaine

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase IV

                          Sponsor : MaineHealth

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Seoul National University Bundang Hospital

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Seoul National University Bundang Hospital

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Ferinject (Ferric Carboxymaltose) is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hip Fractures.

                          Product Name : Ferinject

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          June 23, 2022

                          Lead Product(s) : Ferric Carboxymaltose

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase IV

                          Sponsor : JW Pharmaceutical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : IPACK Block is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Anterior Cruciate Ligament Injuries.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 18, 2022

                          Lead Product(s) : IPACK Block

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          GCS Ramsay Santé

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          GCS Ramsay Santé

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : This drug candidate is currently being evaluated in phase IV clinical studies for the treatment of Knee Injuries.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          September 28, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase IV

                          Sponsor : Euraxi Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Zoledronic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hip Fractures.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 27, 2021

                          Lead Product(s) : Zoledronic Acid

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase IV

                          Sponsor : Lene Bergendal Solberg

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank